Pharmacokinetics of rituximab associated with CHOP chemotherapy in B-cell non-Hodgkin lymphoma

• Published in: Fundamental & clinical pharmacology Vol. 23; no. 5; pp. 601 - 608
• Main Authors: Blasco, Hélène, Chatelut, Etienne, De Bretagne, Isabelle Benz, Congy-Jolivet, Nicolas, Le Guellec, Chantal
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Publishing Ltd 01.10.2009; Blackwell
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal - administration & dosage; Antibodies, Monoclonal - blood; Antibodies, Monoclonal - pharmacokinetics; Antibodies, Monoclonal - therapeutic use; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19 - immunology; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; B-cell non-Hodgkin lymphoma; B-Lymphocytes - cytology; B-Lymphocytes - immunology; Biological and medical sciences; Cyclophosphamide - administration & dosage; Cyclophosphamide - pharmacokinetics; Cyclophosphamide - therapeutic use; Dose-Response Relationship, Drug; Doxorubicin - administration & dosage; Doxorubicin - pharmacokinetics; Doxorubicin - therapeutic use; Drug Administration Schedule; Enzyme-Linked Immunosorbent Assay; Hematologic and hematopoietic diseases; Humans; Infusions, Intravenous; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Lymphocyte Count; Lymphoma, B-Cell - drug therapy; Lymphoma, B-Cell - metabolism; Lymphoma, B-Cell - pathology; Medical sciences; Middle Aged; Neoplasm Staging; pharmacokinetics; Pharmacology. Drug treatments; Pilot Projects; Prednisone - administration & dosage; Prednisone - pharmacokinetics; Prednisone - therapeutic use; R-CHOP chemotherapy; Rituximab; Time Factors; Vincristine - administration & dosage; Vincristine - pharmacokinetics; Vincristine - therapeutic use; Young Adult; Antineoplastic agent; R-CHOP chemotherapy; Rituximab; Malignant hemopathy; B-Lymphocyte; Monoclonal antibody; Non Hodgkin lymphoma; Immunomodulator; CHOP protocol; Treatment; B-cell non-Hodgkin lymphoma; Lymphoproliferative syndrome; Immunotherapy; Immunosuppressive agent; Pharmacokinetics; Cancer

The pharmacokinetics of rituximab administered alone at a dose of 375 mg/m2 once a week have been widely studied but few data are available for the administration of rituximab in combination with other agents. We carried out a pilot pharmacokinetic study in 10 patients with B‐cell non‐Hodgkin lympho...